key: cord-1029771-of0zppci
authors: Ma, Qinhai; Li, Runfeng; Pan, Weiqi; Huang, Wenbo; Liu, Bin; Xie, Yuqi; Wang, Zhoulang; Li, Chufang; Jiang, Haiming; Huang, Jicheng; Shi, Yongxia; Dai, Jun; Zheng, Kui; Li, Xiaobo; Hui, Min; Fu, Li; Yang, Zifeng
title: Phillyrin (KD-1) exerts anti-viral and anti-inflammatory activities against novel coronavirus (SARS-CoV-2) and human coronavirus 229E (HCoV-229E) by suppressing the nuclear factor kappa B (NF-κB) signaling pathway
date: 2020-08-01
journal: Phytomedicine
DOI: 10.1016/j.phymed.2020.153296
sha: b23dda2c7773147aca5ebce1c6b0bf1ab29baafd
doc_id: 1029771
cord_uid: of0zppci

BACKGROUND: : Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has extensively and rapidly spread in the world, causing an outbreak of acute infectious pneumonia. However, no specific antiviral drugs or vaccines can be used. Phillyrin (KD-1), a representative ingredient of Forsythia suspensa, possesses anti-inflammatory, anti-oxidant, and antiviral activities. However, little is known about the antiviral abilities and mechanism of KD-1 against SARS-CoV-2 and human coronavirus 229E (HCoV-229E). PURPOSE: : The study was designed to investigate the antiviral and anti-inflammatory activities of KD-1 against the novel SARS-CoV-2 and HCoV-229E and its potential effect in regulating host immune response in vitro. METHODS: : The antiviral activities of KD-1 against SARS-CoV-2 and HCoV-229E were assessed in Vero E6 cells using cytopathic effect and plaque-reduction assay. Proinflammatory cytokine expression levels upon infection with SARS-CoV-2 and HCoV-229E infection in Huh-7 cells were measured by real-time quantitative PCR assays. Western blot assay was used to determine the protein expression of nuclear factor kappa B (NF-κB) p65, p-NF-κB p65, IκBα, and p-IκBα in Huh-7 cells, which are the key targets of the NF-κB pathway. RESULTS: : KD-1 could significantly inhibit SARS-CoV-2 and HCoV-229E replication in vitro. KD-1 could also markedly reduce the production of proinflammatory cytokines (TNF-α, IL-6, IL-1β, MCP-1, and IP-10) at the mRNA levels. Moreover, KD-1 could significantly reduce the protein expression of p-NF-κB p65, NF-κB p65, and p-IκBα, while increasing the expression of IκBα in Huh-7 cells. CONCLUSIONS: : KD-1 could significantly inhibit virus proliferation in vitro, the up-regulated expression of proinflammatory cytokines induced by SARS-CoV-2 and HCoV-229E by regulating the activity of the NF-кB signaling pathway. Our findings indicated that KD-1 protected against virus attack and can thus be used as a novel strategy for controlling the coronavirus disease 2019.

Coronaviruses (CoVs), which belong to the family Coronaviridae, are positive-sense singlestranded RNA viruses, that infect numerous animals, including birds and mammals (Ksiazek, et al., 2003) . CoVs are common pathogens that easily cause respiratory tract infection and induce different degrees of diseases. These diseases range from upper respiratory tract infections with mild symptoms to lower respiratory tract infections with severe symptoms, including acute tracheitis, pneumonia, bronchitis, and even severe acute respiratory syndrome (SARS) (Heimdal et al., 2019; Owusu et al., 2014; Xu et al., 2020) . SARS-CoV-2 (formerly known as 2019-nCoV, the causative pathogen of coronavirus disease 2019 (COVID-19)), has widely and rapidly spread in the world, causing an outbreak of acute infectious pneumonia (Du, 2020; Carlos et al., 2020) .

COVID-19 is a major CoV infection that has threatened human life after SARS and Middle East respiratory syndrome (MERS), causing severe respiratory illness and even death (Zaki et al., 2012) . Despite a series of extraordinary social-alienation measures in various countries, the number of people infected continues to rise. Moreover, the population's susceptibility to these highly pathogenic CoVs has contributed to large outbreaks and evolved into public health events: thereby highlighting the necessity to prepare for future re-emergence or novel emerging viruses (Nkengasong, 2020) . For this sudden and lethal disease, no specific antiviral drugs or vaccines can be used. Therefore, identifying effective antiviral agents to combat the disease is urgently needed.

At present, some drugs can effectively eliminate SARS-CoV-2 and improve symptoms.

These drugs are reportedly effective in vitro, such as fusion peptide (EK1) (Xia et al., 2019) , abidol (Coleman et al., 2016) , RNA-synthesis inhibitors (eg., TDF and 3TC), and anti-inflammatory drugs (eg., hormones and other molecules). However, the efficacy and safety of drugs for SARS-CoV-2 pneumonia patients require further assessment through clinical trials.

A novel CoV pneumonia diagnosis and treatment plan jointly issued by the National Health Committee of the People's Republic of China and the National Administration of traditional Chinese medicine has classified COVID-19 into the category of "pestilence" in Traditional Chinese Medicine (TCM). In the third edition, part of "TCM treatment" for COVID-19 has been added, whereas the sixth edition describes the syndromes, tongue picture, and pulse throughout different periods of the disease, as well as recommends the relevant prescriptions and proprietary Chinese medicine. A previous report has indicated that the respiratory symptoms of four patients with mild or severe COVID-19 were cured or significantly improved after treatment with lopinavir/ritonavir, abidol, and Shufeng Jiedu Capsule on the basis of supportive nursing (ZW et al., 2020) . Another retrospective analysis of clinical records conducted in SARS-CoV-2 infected patients at Wuhan Ninth Hospital and CR & WISCO General Hospital has shown that Lianhuaqingwen combination could significantly relieve cardinal symptoms and reduce the course of COVID-19 (Yao et al.,2020) . Accordingly, studying the TCMs that have obvious advantages in the treating the new virus is important.

Forsythia suspensa (Thunb.) is a popular traditional Chinese medicine used to treat pyrexia and infections (Guo et al., 2007; Lua et al., 2010; . Phillyrin (KD-1), a representative ingredient of F. suspensa, has anti-inflammatory (Diaz et al., 2001) , anti-oxidant Gulcin et al., 2006) , and antiviral activities (Chen et al., 2004) . A previous report has showed that KD-1 could inhibit inflammation in LPS-stimulated RAW264.7 macrophages in vitro, which is supposed to be linked with the restrained JAK-STAT and p38 MAPK signal pathways and decreased expression of ROS (Pan et al., 2014) . KD-1 shows phosphodiesterase-4 inhibitory activities in phosphodiesterase assay and reduces LPS-mediated TNF release in RAW264.7 and PBMC cells in vitro (Coon et al., 2014) . Moreover, KD-1 (10, 20 mg/kg) suppresses the pulmonary histopathologic changes, alveolar hemorrhage, and neutrophil infiltration in an acute lung-injury mice model in vivo. It exerts protective effects against lung inflammation by down-regulating the contents of TNF-α, IL-1β, IL-6, and myeloperoxidase (Zhong et al., 2013) . We have also found that KD-1 exerts antiviral effects in different respiratory tract viruses, including influenza virus, parainfluenza virus, and respiratory syncytial virus in vitro.

However, the effectiveness of KD-1 in the treatment of CoV is not confirmed, and its mechanisms of action remain obscure. Accordingly, we evaluated the antiviral and anti-inflammatory efficiencies of KD-1 against a clinical isolate of SARS-CoV-2 and human coronavirus 229E In the present study, the antiviral and anti-inflammatory effects of KD-1 on SARS-CoV-2 and HCoV-229E infection in vitro were comprehensively evaluated. Results demonstrated that KD-1 inhibited virus replication in a dose-dependent manner. KD-1 could also markedly decrease the expression of proinflammatory cytokines in infected human hepatocellular carcinoma cell lines (Huh-7) by inhibiting the transcription factor nuclear factor kappa B (NF-κB) signal in Huh-7 cells. Our finding can help elucidate the mechanism of KD-1 against SARS-CoV-2 and HCoV-229E infection.

The KD-1 (lot: 20190201) 

African green monkey kidney epithelial (Vero E6) cells and human hepatocellular carcinoma cell lines (Huh-7) were purchased from ATCC. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, USA) with 10 % fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin. The SARS-CoV-2 (Genebank accession no. MT123290.1) was clinically isolated from the First Affiliated Hospital of Guangzhou Medical University, and HCoV-229E (ATCC ® VR740™) was purchased from ATCC. The viruses were propagated and adapted as previously described . The 50 % tissue culture infective dose (TCID 50 ) of SARS-CoV-2 and HCoV-229E were determined using the Reed-Muench method (TCID 50 = 10 -6 /100 μL and TCID50=10 -5.5 /μL, respectively). Virus stocks were collected and stored at -80 °C.

The infection experiments of SARS-CoV-2 were performed in a biosafety level-3 laboratory and those of HCoV-229E were performed in a biosafety level-2 laboratory.

The cytotoxic effects of the KD-1 on Vero E6 and Huh-7 cells were evaluated by MTT assay . Briefly, Vero E6 (5 × 10 4 cells/well) and Huh-7 (5 × 10 4 cells/well) cells grown in monolayer in 96-well plates were rinsed with PBS followed by incubation with indicated concentrations of KD-1. After 72 h, the cells were stained with 0.5 mg/mL MTT solution for 4 h.

The supernatants were removed, and the formed formazan crystals were dissolved in 100 μL of DMSO. The absorbance at 570 nm was determined using a Multiskan Spectrum reader (Thermo Fisher, USA). The 50 % toxicity concentration (TC 50 ) of KD-1 causing 50 % death of cells was calculated.

To investigate the antiviral effects of KD-1 against SARS-CoV-2 and HCoV-229E, we performed CPE inhibition assay with a nontoxic concentration of KD-1. Briefly, Vero E6 cell monolayers were grown in 96-well plates and inoculated with 100 TCID 50 of CoV strains at 37 C for 2 h. The inoculum was removed, and the cells were subsequently incubated with indicated concentrations of KD-1. Following 72 h of incubation, the infected cells showed 100 % CPE under a microscope. The percentage of CPE in KD-1-treated cells was recorded. The 50 % inhibition concentration (IC 50 ) of the virus-induced CPE by KD-1 was calculated as described, and the selectivity index (SI) was determined from the ratio of TC 50 to IC 50 (Reed et al., 1938) .

Plaque-reduction assay was performed as previously described. Briefly, monolayer Vero E6 cells in 6-well plates were rinsed with PBS and incubated with 100 plaque-forming unit of SARS-CoV-2 and HCoV-229E. Following 2 h of incubation, the inoculum was removed and the cells were overlaid by 2 mL of agar/basic medium mixture, which contained 0.8 % agar and indicated concentrations of KD-1. The plates were then incubated in 37 ℃ for 72 h, followed by fixation with 4 % formalin for 30 min. The overlays were then removed and stained with 0.1 % crystal violet for 3min. The plaques were visualized and counted (Reed et al., 1938) .

To determine the possible mechanisms underlying the antiviral activity of KD-1, we used several drug concentrations with high antiviral efficiency for subsequent experiments. The primers of TNF-α, IL-6, MCP-1, IL-1β, IP-10, and GAPDH genes (Table 1) were designed using Primer 5.0.

Briefly, Huh-7 cells grown in 12-well plates were rinsed with PBS and then exposed to CoV at a multiplicity of infection (MOI) of 1 for 2 h. The inoculums were removed after infection, and the cells were divided into the following six groups: normal control group (NC), virus-infected group (virus), and three groups with various of KD-1 concentrations. The cells were harvested at 48 h. Total RNA from the different groups was extracted in accordance with the specification of RNA reagent (Invitrogen, MA, USA), and reverse transcription of RNAs was quantified by using the PrimeScript™ RT Master Mix kit (Takara Bio, Japan). RT-PCR was then performed on cDNA samples by using SYBR Premix Ex Tap™ II (Takara Bio, Japan). PCR data were analyzed with ABI PRISM® 7500 Real-time PCR detection system (Applied Biosystems Co., USA). The relative amount of PCR products was calculated using the 2−ΔΔCt method as previously described (Pfaffl et al., 2001) . 

All data in this study were analyzed by using analysis of variance (ANOVA) with SPSS ver.

19.0 (Armonk, NY, USA). Data were presented as the mean ± standard deviation. Differences in multiple groups were determined by one-way ANOVA analysis of variance with Tukey's honest significant difference (HSD) test. P-value＜0.05 was considered statistically significant.

The cytotoxicity of KD-1 in Vero E6 and Huh-7 cells was evaluated by non-radioactive cell HCoV-229E was 64.53 μg/mL ( Figure 2B ). The SI of KD-1 was 16.02. These results showed that KD-1 could protect cells from virus-induced cell death in a dose-dependent manner, and that the antiviral capability of KD-1 on SARS-CoV-2 was better than that on HCoV-229E.

A plaque-reduction assay was conducted to confirm the efficacy of KD-1 on SARS-CoV-2 ( Figures 1C and 1D ) and HCoV-229E ( Figures 2C and 2D) propagation. Vero E6 and Huh-7 cells were infected with SARS-CoV-2 (MOI=0.1) and HCoV-229E (MOI=0.1), respectively. The cells were also incubated with overlay medium containing various KD-1 concentrations. After 3 days, the overlays were removed and stained with 0.1 % crystal violet. The plaques were visualized and counted. Results showed that the average size and plaque number in KD-1-treated cells were markedly reduced in a dose-dependent manner. CPE and plaque-reduction assays showed that KD-1 may be a key parameter influencing SARS-CoV-2 and HCoV-229E activities. 

Infections by CoVs (including SARS-CoV-2 and HCoV-229E) can induce a strong inflammatory reaction, as hallmarked by the production of cytokines and chemokines.

Accordingly, the influence of KD-1 on infected cells was examined by measuring cytokines. To determine the influence of KD-1 on the expression of proinflammatory cytokines induced by SARS-CoV-2 and HCoV-229E, the mRNA expression levels of IL-6, TNF-α, IL-1β, IP-10, and MCP-1 in Huh-7 cells were detected by RT-qPCR. As shown in Figures 3 and 4 

To further explore the mechanisms underlying the antiviral activity of KD-1, we examined the expression of proteins related to NF-κB signaling in Huh-7 cells infected by SARS-CoV-2 and HCoV-229E. Western blot analysis was performed using the cell lysates of Huh-7 cells treated with or without KD-1 to analyze the protein expression levels of NF-κB p65, p-NF-κB p65, IκBα, and p-IκBα. As shown in Figures 5 and 6 , the expression levels of NF-κB p65, p-NF-κB p65, and p-IκBα of the virus group were markedly higher than those of the NC group (p < 0.01), and the expression levels of IκBα of the virus group were markedly lower than those of the NC group (p < 0.01). Compared with the virus group, the protein expression levels of the NF-κB p65, p-NF-κB p65 were significantly reduced in Huh-7 cells with KD-1 (250, 125, and 62.5 μg/mL), and p-IκBα was significantly reduced in Huh-7 cells with KD-1 (250 and 125 μg/mL). Meanwhile, IκBα was significantly up-regulated in Huh-7 cells with KD-1 (250, 125, and 62.5 μg/mL). 

The number of infections caused by the newly emerged SARS-CoV-2 continues to rise sharply in China (CDC, 2020; WHO, 2020) . The extensive and rapid spread of this virus in the world has caused an outbreak of acute infectious pneumonia (Guang et al., 2020) . It is a major

CoV infection that has threatened human life after SARS and MERS (Mahase, 2020) . No specific antiviral drugs or vaccines can be used for this sudden and lethal disease, and the supportive care and nonspecific treatment of the patient is the only option to ameliorate the symptoms (Clercq, 2020; Russell et al., 2020; Zumla et al., 2020) . Thus, effective and safe antiviral agents are urgently needed. Nowadays, the use of TCM is a popular and acceptable therapy, and many TCM and 16.02, respectively. All these results confirmed that KD-1 may be a key parameter influencing its viral activity.

Highly pathogenic CoVs, such as SARS-CoV and MERS-CoV reportedly cause fatal pneumonia, which is mainly associated with rapid virus replication, massive inflammatory cell infiltration, and elevated proinflammatory cytokine/chemokine responses. Although the pathophysiology of fatal pneumonia caused by highly pathogenic CoVs is not completely understood, recent studies suggest the crucial role of cytokine storm in causing fatal pneumonia (Channappanavar et al., 2017) . Previous studies have shown increased amounts of proinflammatory cytokines (e.g., IL-1β, IL-6, IP-10, and MCP-1) in sera of SARS patients (Leong et al., 2006) , which was similar in the serum of MERS patients with increased concentrations of proinflammatory cytokines (IFN-γ, TNF-α, IL-15, and IL-17) (Assiri et al., 2013) . Moreover, it was reported that the occurrence of cytokine storm in NCIP patients in the ICU but not in non-ICU patients . They detected the production of IL-1β, TNF-α, MCP-1, IP-10, and IL-6 induced by SARS-COV-2 and HCoV-229E. Meanwhile, our results showed that KD-1 inhibited the release of IL-1β, TNF-α, MCP-1, IP-10, and IL-6 induced by SARS-COV-2 and

HCoV-229E in Huh-7 cells (Figures 3 and Figure 4 ) in a dose-dependent manner.

The SARS syndrome is characterized by uncontrolled inflammatory response, and NF-κB is the major transcription factor activated in acute respiratory distress syndrome (Fan et al., 2001) .

Similar to SARS-CoV, SARS-CoV-2 can also cause severe respiratory illness and even death. We performed RNA-seq of SARS-COV-2 virus-infected Huh-7 cells using the Illumina HiSeq 2000 platform and found that SARS-CoV-2 infection could regulate the NF-κB, TNF and PI3K-Akt signaling pathway, as well as ECM-receptor interaction (data not shown). NF-кB plays an important role in mediating inflammation, immune responses, and other cellular activities (Mitchell et al., 2016) . NF-кB activation can induce cytokine production, and these cytokines can react in turn, produce a positive autoregulatory loop and exacerbate the inflammatory response (Santoro et al., 2003) . Accordingly, to understand the molecular mechanism of KD-1 action against CoV infection, we examined how the regulation of the NF-кB signaling pathway contributed to the alleviation of inflammation. . Results showed that HCoV-229E activated the NF-кB signaling pathway, and that KD-1 could significantly decrease the HCoV-229E -induced activation of p-NF-κB p65 and p-IκBα, and increase the expression of IκBα (Figures 5 and 6 ). We inferred that the mechanism underlying the antiviral activity of the KD-1 involved the impairment of the up-regulated pro-inflammatory cytokines induced by CoV by inhibiting the activity of the NF-кB signaling pathway. The change in cytokine profiles suggested that KD-1 may affect the inhibition of cytokine storm induced by CoV, and this deduction should be validated in vivo.

Our results revealed that KD-1 could significantly protect cells from CoV-induced cell death and inhibit the average size and plaque number of the virus in vitro. The anti-CoV effect was attributed to the blocking of virus replication and the inhibition of the CoV-induced up-regulated expression of pro-inflammatory cytokines by a regulating the activity of the NF-кB signaling pathway. Thus, further evaluation of KD-1 as an anti-SARS-CoV-2 agent is need. Our finding can serve as a reference to further reveal the mechanisms underlying the anti-inflammatory activity of KD-1 and its potential use to treat SARS-CoV-2-induced inflammation.

Qinhai Ma and Zifeng Yang designed the study. Qinhai Ma and Runfeng Li wrote the paper. Li Fu thoroughly revised the manuscript. All authors read and approved the final manuscript.

The authors declare no conflict of interest. All data were generated in-house, and no paper mill was used. All authors agree to be accountable for all aspects of work ensuring integrity and accuracy.

A novel coronavirus associated with severe acute respiratory syndrome

Human Coronavirus in Hospitalized Children with Respiratory Tract Infections: A 9-Year Population-Based Study from Norway

Human coronaviruses associated with upper respiratory tract infections in three rural areas of Ghana

Imaging features of 2019 novel coronavirus pneumonia

Outbreak of a novel coronavirus

2020. Novel Wuhan

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

China's response to a novel coronavirus stands in stark contrast to the 2002 SARS outbreak response

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Clinical Characteristics of 138 Hospitalized Patients With

Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike

Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion

Clinical characteristics and therapeutic procedure for four cases with

Retrospective clinical analysis of treating pneumonia caused by new coronavirus infection with Chinese medicine lianhua clearing disease

Characterization of phenolic compounds in the fruits of Forsythia suspensa by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Protective effects of Forsythia suspensa extract against oxidative stress induced by diquat in rats

Determination of phillyrin and forsythoside A in Forsythia suspensa from different localities by HPLC

Lignan and phenylpropanoid glycosides from Phillyrea latifolia and their in vitro anti-inflammatory activity

Lignans from the flowers of Osmanthus fragrans var. aurantiacus and their inhibition effect on NO production

Antioxidant activity of lignans from fringe tree (Chionanthus virginicus L.)

Simultaneous determi-nation of some active ingredients in anti-viral preparations of traditional Chinese medicine by micellar electrokinetic chromatogra-phy

Forsythin inhibits lipopolysaccharide-induced inflammation by suppressing JAK-STAT and p38 MAPK signalings and ROS production

Novel PDE4 inhibitors derived from Chinese medicine Forsythia

Phillyrin attenuates LPS-induced pulmonary inflammation via suppression of MAPK and NF-κB activation in acute lung injury mice

A Novel Coronavirus from Patients with Pneumonia in China

Korean Scutellaria baicalensis water extract inhibits cell cycle G1/S transition by suppressing cyclin D1 expression and matrix-metalloproteinase-2 activity in human lung cancer cells

A simple method of estimating fifty percent endpoints

A new mathematical model for relative quantification in real-time RT-PCR

Scanning electron microscope examination of epithelial cells infected with enveloped viruses

Distribution of 2019-nCoV infection

WHO. Novel coronavirus (2019-nCoV) situation report-27

Clinical characteristics of 2019 novel coronavirus infection in China

China coronavirus: WHO declares international emergency as death toll exceeds 200

Therapeutic options for the 2019 novel coronavirus (SARS-CoV-2)

Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 lung injury. The Lancet

Reducing mortality from: host-directed therapies should be an option. The Lancet

Modern uses of electron microscopy for detection of viruses

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Clinical and laboratory findings of SARS in Singapore

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Transcriptional mechanisms of acute lung injury

Signaling via the NF-κB system

NF-κB and virus infection: who controls whom